Scientific article
OA Policy
English

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy

Published in

Core evidence, vol. 11, p. 37-47

Publication date

2016

Abstract

Gaucher disease is the first lysosomal disease to benefit from enzyme replacement therapy, thus serving as model for numerous other lysosomal diseases. Alglucerase was the first glucocerebrosidase purified from placental extracts, and this was then replaced by imiglucerase - a Chinese hamster ovary cell-derived glucocerebrosidase.

Citation (ISO format)

DE ROUX SERRATRICE, Christine et al. Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. In: Core evidence, 2016, vol. 11, p. 37–47. doi: 10.2147/CE.S93717

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1555-1741
487views
539downloads

Technical informations

Creation

09/11/2016 12:29:00

First validation

09/11/2016 12:29:00

Update

15/03/2023 01:04:25

Status update

15/03/2023 01:04:24

Last indexation

31/10/2024 05:22:45
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated